CAR T cell News and Research

RSS

Researchers develop new way to genetically engineer T cells for treating leukemia relapse

Researchers at Fred Hutchinson Cancer Research Center and the University of Washington have developed a novel way to genetically engineer T cells that may be effective for treating and preventing leukemia relapse.

25 Oct 2017

Dana-Farber, Brigham and Women's Cancer Center certified to offer new CAR T-cell therapy

Following a successful clinical trial involving Dana-Farber Cancer Institute and Brigham and Women's Hospital, the first chimeric antigen receptor (CAR) T-cell therapy for adult cancers was approved by the Food and Drug Administration today.

20 Oct 2017

New CAR-T cell therapy offers effective option for certain blood cancer patients

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers.

19 Oct 2017

Cascade of costs could push new gene therapy above $1 million per patient

Outrage over the high cost of cancer care has focused on skyrocketing drug prices, including the $475,000 price tag for the country's first gene therapy, Novartis' Kymriah, a leukemia treatment approved in August.

17 Oct 2017

Study provides detailed characterization of neurotoxicity arising from CD19 CAR T-cell therapy

New potential biomarkers and a novel algorithm could help identify patients at increased risk of suffering from severe neurotoxicity after receiving CD19 CAR T-cell therapy. The study extensively characterized common and occasionally fatal side effects of this immunotherapy.

12 Oct 2017

New gene therapy to treat cancer in children, young adults offers hopes and challenges

The first gene therapy for cancer, approved by the Food Drug Administration in August, will transform the treatment of a particular kind of cancer in children and young adults. It's transformative because it uses a patient's own immune cells to attack the cancer cells.

3 Oct 2017

UChicago Medicine working with Novartis to offer breakthrough gene therapy for pediatric ALL patients

The University of Chicago Medicine is one of a limited number of U.S. sites working to offer a breakthrough gene therapy for pediatric acute lymphoblastic leukemia (ALL), which was just approved by the U.S. Food and Drug Administration.

31 Aug 2017

FDA makes the first gene therapy Kymriah available for treatment of pediatric ALL

The U.S. Food and Drug Administration (FDA) has issued a press release making the first even gene therapy available for treatment of children with a form of acute lymphoblastic leukemia (ALL).

30 Aug 2017

$Novartis gets FDA approval for novel immunocellular therapy to treat relapsed or refractory B-cell ALL$

Novartis gets FDA approval for novel immunocellular therapy to treat relapsed or refractory B-cell ALL

Novartis announced today that the US Food and Drug Administration has approved Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.

30 Aug 2017

Pioneering cancer gene therapy gets green light — and $475,000 price tag

The country's first approved gene therapy — approved Wednesday to fight leukemia that resists standard therapies — will cost $475,000 for a one-time treatment, its manufacturer announced.

30 Aug 2017

FDA approves first cell-based gene therapy for use in the United States

The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases.

30 Aug 2017

‘Breakthrough’ leukemia drug also portends ‘quantum leap’ in cost

When doctors talk about a new leukemia drug from Novartis, they ooze enthusiasm, using words like "breakthrough," "revolutionary" and "a watershed moment."

23 Aug 2017

Cord-blood-derived natural killer cells can be modified to destroy B-cell cancers

Immune cells with a general knack for recognizing and killing many types of infected or abnormal cells also can be engineered to hunt down cells with specific targets on them to treat cancer, researchers at The University of Texas MD Anderson Cancer Center report in the journal Leukemia.

13 Jul 2017

New immunotherapy sends multiple myeloma into remission

Researchers are reporting the impressive results of a new cell and gene therapy that has achieved unprecedented success in treating multiple myeloma patients. Although the study is an early one and the population only included 35 people, every one of the patients responded to the treatment and 33 (94%) were in some degree of clinical remission within two months.

6 Jun 2017

Small clinical trial reveals promising results of triple immunotherapy in treating rare skin cancer

Three out of four patients treated with an experimental combination of three different therapies for the rare skin cancer known as Merkel cell carcinoma are in complete remission following the treatment, according to study results from a small clinical trial led at Fred Hutchinson Cancer Research Center.

31 May 2017

Scientists discover simple way to use light for steering killer immune cells toward tumors

The science behind harnessing the immune system to fight cancer is complicated, but a University of Rochester Medical Center laboratory discovered a simple, practical way to use light and optics to steer killer immune cells toward tumors.

15 May 2017

New trial aims to prolong remission for pediatric leukemia patients treated with T-cell immunotherapy

After phase 1 results of Seattle Children's Pediatric Leukemia Adoptive Therapy trial have shown T-cell immunotherapy to be effective in getting 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia into complete initial remission, researchers have now opened a first-in-human clinical trial aimed at reducing the rate of relapse after the therapy, which is about 50 percent.

9 May 2017

Nanoparticle-programmed immune cells can slow progression of leukemia in mouse model

Researchers at Fred Hutchinson Cancer Research Center have developed biodegradable nanoparticles that can be used to genetically program immune cells to recognize and destroy cancer cells -- while the immune cells are still inside the body.

17 Apr 2017

City of Hope researchers to highlight basic cancer research and population studies at AACR meeting

City of Hope, a world-renowned independent research and cancer and diabetes treatment center, will highlight a variety of basic research and population studies at the annual meeting of the American Association for Cancer Research at the Walter E. Washington Convention Center in Washington, D.C., April 1 to 5.

28 Mar 2017

New biomarker 'Bim' could help predict optimal treatment for metastatic melanoma patients

Over the past few years, checkpoint blockade immunotherapies have revolutionized cancer treatment and helped many patients who were previously considered untreatable.

8 Mar 2017

CAR T cell News and Research

Researchers develop new way to genetically engineer T cells for treating leukemia relapse

Dana-Farber, Brigham and Women's Cancer Center certified to offer new CAR T-cell therapy

New CAR-T cell therapy offers effective option for certain blood cancer patients

Cascade of costs could push new gene therapy above $1 million per patient

Study provides detailed characterization of neurotoxicity arising from CD19 CAR T-cell therapy

New gene therapy to treat cancer in children, young adults offers hopes and challenges

UChicago Medicine working with Novartis to offer breakthrough gene therapy for pediatric ALL patients

FDA makes the first gene therapy Kymriah available for treatment of pediatric ALL

Novartis gets FDA approval for novel immunocellular therapy to treat relapsed or refractory B-cell ALL

Pioneering cancer gene therapy gets green light — and $475,000 price tag

FDA approves first cell-based gene therapy for use in the United States

‘Breakthrough’ leukemia drug also portends ‘quantum leap’ in cost

Cord-blood-derived natural killer cells can be modified to destroy B-cell cancers

New immunotherapy sends multiple myeloma into remission

Small clinical trial reveals promising results of triple immunotherapy in treating rare skin cancer

Scientists discover simple way to use light for steering killer immune cells toward tumors

New trial aims to prolong remission for pediatric leukemia patients treated with T-cell immunotherapy

Nanoparticle-programmed immune cells can slow progression of leukemia in mouse model

City of Hope researchers to highlight basic cancer research and population studies at AACR meeting

New biomarker 'Bim' could help predict optimal treatment for metastatic melanoma patients

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News